Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Blumenfeld

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Neurology|February 20, 2025
Real-world Evidence of Adding Atogepant to OnabotulinumtoxinA for Control of Chronic Migraine: A Retrospective Chart Review (P4-12.001)Andrew Blumenfeld, Laszlo Mechtler, Lisa Cook, et al.
Therapeutic Advances in Neurological Disorders|June 6, 2022
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature reviewChristopher Gottschalk, Dawn C Buse, Michael J Marmura, et al.
Headache|July 13, 2010
Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: Results of the American Headache Society Interventional Procedure Survey (AHS-IPS)Andrew Blumenfeld, Avi Ashkenazi, Brian Grosberg, et al.
Headache|May 22, 2010
Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future researchAvi Ashkenazi, Andrew Blumenfeld, Uri Napchan, et al.
Health and Quality of Life Outcomes|November 19, 2017
Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID)Asha Hareendran, Sally Mannix, Anne Skalicky, et al.
Pain and Therapy|April 17, 2026
Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL TrialAmaal J Starling, David Kudrow, Neha Kapur, et al.
Headache|June 13, 2008
The headache management trial: a randomized study of coordinated careDavid B Matchar, Linda Harpole, Gregory P Samsa, et al.
Cephalalgia : an International Journal of Headache|April 7, 2026
Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label studyJohn Rothrock, Umer Najib, Jessica Ailani, et al.
Advances in Therapy|November 9, 2022
Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting SystemStephen D Silberstein, Shoshana Reshef, Joshua M Cohen, et al.
Cephalalgia : an International Journal of Headache|February 5, 2023
Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trialsRichard B Lipton, Andrew Blumenfeld, Christopher M Jensen, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Neurology|February 20, 2025
Real-world Evidence of Adding Atogepant to OnabotulinumtoxinA for Control of Chronic Migraine: A Retrospective Chart Review (P4-12.001)Andrew Blumenfeld, Laszlo Mechtler, Lisa Cook, et al.
Therapeutic Advances in Neurological Disorders|June 6, 2022
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature reviewChristopher Gottschalk, Dawn C Buse, Michael J Marmura, et al.
Headache|July 13, 2010
Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: Results of the American Headache Society Interventional Procedure Survey (AHS-IPS)Andrew Blumenfeld, Avi Ashkenazi, Brian Grosberg, et al.
Headache|May 22, 2010
Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future researchAvi Ashkenazi, Andrew Blumenfeld, Uri Napchan, et al.
Health and Quality of Life Outcomes|November 19, 2017
Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID)Asha Hareendran, Sally Mannix, Anne Skalicky, et al.
Pain and Therapy|April 17, 2026
Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL TrialAmaal J Starling, David Kudrow, Neha Kapur, et al.
Headache|June 13, 2008
The headache management trial: a randomized study of coordinated careDavid B Matchar, Linda Harpole, Gregory P Samsa, et al.
Cephalalgia : an International Journal of Headache|April 7, 2026
Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label studyJohn Rothrock, Umer Najib, Jessica Ailani, et al.
Advances in Therapy|November 9, 2022
Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting SystemStephen D Silberstein, Shoshana Reshef, Joshua M Cohen, et al.
Cephalalgia : an International Journal of Headache|February 5, 2023
Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trialsRichard B Lipton, Andrew Blumenfeld, Christopher M Jensen, et al.
Pageof 5